Harvard Bioscience (HBIO) Curent Deferred Tax Liability (2014 - 2015)
Harvard Bioscience (HBIO) reported Curent Deferred Tax Liability of $2.2 million for Q4 2015, up 1756.2% year-over-year from $121000.0 in Q4 2014, and up 820.49% on a QoQ basis from $244000.0 in Q3 2015.
Harvard Bioscience (HBIO) has 2 years of Curent Deferred Tax Liability data on file, last reported at $2.2 million in Q4 2015.
- Quarterly Curent Deferred Tax Liability rose 1756.2% year-over-year to $2.2 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $2.2 million (up 1756.2% YoY) and the FY2015 annual result came in at $2.2 million, up 1756.2% from the prior year.
- Curent Deferred Tax Liability improved to $2.2 million in Q4 2015 per HBIO's latest filing, from $244000.0 in the prior quarter.
- Across five years, Curent Deferred Tax Liability topped out at $2.2 million in Q4 2015 and bottomed at $121000.0 in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn | - |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn | - |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn | - |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn | - |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn | - |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn | - |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn | - |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn | - |
| 10 | Harvard Bioscience | 25.38 Mn | 18.29 Mn | 12.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 2.25 Mn |
| Dec 31, 2015 | 2.25 Mn |
| Sep 30, 2015 | 244,000.00 |
| Sep 30, 2015 | 244,000.00 |
| Jun 30, 2015 | 246,000.00 |
| Jun 30, 2015 | 246,000.00 |
| Mar 31, 2015 | 239,000.00 |
| Mar 31, 2015 | 239,000.00 |
| Dec 31, 2014 | 121,000.00 |
| Dec 31, 2014 | 121,000.00 |